24/7 Patient Assistance: 760-405-8205

David Kelsen, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Lung Cancer

specialties & services

  • Bio & Insurance Information

    Dr. David Kelsen graduated from Hahnemann School Of Medicine affiliated to Allegheny University of Health Sciences in 1972, following which he did his internship at Temple University Hospital that was complete by the year 1973. He completed his residency program in 1976 at Temple University Hospital and a fellowship at Memorial Sloan-Kettering Cancer Center, in the year 1977. He is board-certified in the field of internal medicine and oncology. Currently, he works at Memorial Sloan-Kettering Cancer Center and has contributed to three research papers.


  • Education & Training

    dept_icon

    Hahnemann School Of Medicine, Allegheny University Of Health Sciences Graduated in 1972

    Medical School

    dept_icon

    Temple University Hospital Completed in 1973

    Internship

    dept_icon

    Temple University Hospital Completed in 1976

    Residency

    dept_icon

    Memorial Sloan-Kettering Cancer Center Completed in 1977

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Memorial Sloan Kettering Cancer Center

    Languages: English/Spanish

    (212) 639-2000

    1275 York Ave

    New York, New York 10065

    Read More
  • Publications & Memberships

    Dr. David Kelsen has contributed to 3 publications.

    Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

    Ku GY1, Kriplani A2, Janjigian YY1, Kelsen DP1, Rusch VW3, Bains M3, Chou J4, Capanu M4, Wu AJ5, Goodman KA6, Ilson DH1.

    See more >>

    MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing.

    Tahover E1, Bar Shalom R, Bogot N, Kelsen D, Gabizon A.

    See more >>

    Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

    Yaeger R1, Shah MA2, Miller VA3, Kelsen JR4, Wang K5, Heins ZJ6, Ross JS3, He Y3, Sanford E3, Yantiss RK7, Balasubramanian S3, Stephens PJ3, Schultz N8, Oren M9, Tang L10, Kelsen D

    See more >>